These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37084305)

  • 21. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.
    Mei S; Fan Z; Liu X; Zhao F; Huang Y; Wei L; Hu Y; Xie Y; Wang L; Ai B; Liang C; Xu F; Guo F
    Front Immunol; 2022; 13():911164. PubMed ID: 35935962
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective.
    Borkotoky S; Dey D; Hazarika Z
    Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural basis of severe acute respiratory syndrome coronavirus 2 infection.
    Ge J; Zhang S; Zhang L; Wang X
    Curr Opin HIV AIDS; 2021 Jan; 16(1):74-81. PubMed ID: 33186231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding and combating COVID-19 using the biology and chemistry of SARS-CoV-2.
    Khan MM; Goh YW; Ahmad N; Siddique MM
    Bioprocess Biosyst Eng; 2022 Nov; 45(11):1753-1769. PubMed ID: 36125525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
    Braun J; Loyal L; Frentsch M; Wendisch D; Georg P; Kurth F; Hippenstiel S; Dingeldey M; Kruse B; Fauchere F; Baysal E; Mangold M; Henze L; Lauster R; Mall MA; Beyer K; Röhmel J; Voigt S; Schmitz J; Miltenyi S; Demuth I; Müller MA; Hocke A; Witzenrath M; Suttorp N; Kern F; Reimer U; Wenschuh H; Drosten C; Corman VM; Giesecke-Thiel C; Sander LE; Thiel A
    Nature; 2020 Nov; 587(7833):270-274. PubMed ID: 32726801
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perspectives on development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
    Zhang C; Zhou C; Shi L; Liu G
    Hum Vaccin Immunother; 2020 Oct; 16(10):2366-2369. PubMed ID: 32961082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The genetic sequence, origin, and diagnosis of SARS-CoV-2.
    Wang H; Li X; Li T; Zhang S; Wang L; Wu X; Liu J
    Eur J Clin Microbiol Infect Dis; 2020 Sep; 39(9):1629-1635. PubMed ID: 32333222
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dynamics of binding ability prediction between spike protein and human ACE2 reveals the adaptive strategy of SARS-CoV-2 in humans.
    Xue X; Shi J; Xu H; Qin Y; Yang Z; Feng S; Liu D; Jian L; Hua L; Wang Y; Zhang Q; Huang X; Zhang X; Li X; Chen C; Guo J; Tang W; Liu J
    Sci Rep; 2021 Feb; 11(1):3187. PubMed ID: 33542420
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
    Li J; Wang P; Tracey KJ; Wang H
    Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of SARS-CoV-2 Spike Mutations during Prolonged Infection in Immunocompromised Hosts.
    Ko KKK; Yingtaweesittikul H; Tan TT; Wijaya L; Cao DY; Goh SS; Abdul Rahman NB; Chan KXL; Tay HM; Sim JHC; Chan KS; Oon LLE; Nagarajan N; Suphavilai C
    Microbiol Spectr; 2022 Jun; 10(3):e0079122. PubMed ID: 35543562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19.
    Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE
    J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
    Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
    J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
    Choudhury A; Mukherjee S
    J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2.
    Liu Z; Xiao X; Wei X; Li J; Yang J; Tan H; Zhu J; Zhang Q; Wu J; Liu L
    J Med Virol; 2020 Jun; 92(6):595-601. PubMed ID: 32100877
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains.
    Qing E; Kicmal T; Kumar B; Hawkins GM; Timm E; Perlman S; Gallagher T
    mBio; 2021 Aug; 12(4):e0159021. PubMed ID: 34340537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.
    Di Paola L; Hadi-Alijanvand H; Song X; Hu G; Giuliani A
    J Proteome Res; 2020 Nov; 19(11):4576-4586. PubMed ID: 32551648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A molecular docking study revealed that synthetic peptides induced conformational changes in the structure of SARS-CoV-2 spike glycoprotein, disrupting the interaction with human ACE2 receptor.
    Souza PFN; Lopes FES; Amaral JL; Freitas CDT; Oliveira JTA
    Int J Biol Macromol; 2020 Dec; 164():66-76. PubMed ID: 32693122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice.
    Martinez DR; Schäfer A; Leist SR; De la Cruz G; West A; Atochina-Vasserman EN; Lindesmith LC; Pardi N; Parks R; Barr M; Li D; Yount B; Saunders KO; Weissman D; Haynes BF; Montgomery SA; Baric RS
    Science; 2021 Aug; 373(6558):991-998. PubMed ID: 34214046
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.